Rabinovitch N, Gelfand E W
National Jewish Medical and Research Center, Denver, CO 80206, USA.
Curr Opin Pediatr. 1998 Jun;10(3):243-9. doi: 10.1097/00008480-199806000-00004.
In the past year, a number of important advances were made in the treatment of asthma, particularly with regard to children. New guidelines stress anti-inflammatory treatment early after diagnosis for patients who have persistent symptoms. Recent studies confirmed that inhaled steroids are the most efficacious therapy for children with mild asthma, although these same studies demonstrate the potential for adverse effects as well. Combination therapy with theophylline or salmeterol may allow clinicians to minimize the dose of inhaled steroids while controlling symptoms. New high-potency inhaled steroid preparations are clearly effective in the treatment of severely asthmatic patients, but they may cause significant side effects at higher doses. Anti-leukotriene medications may be helpful in the management of persistent asthma because they have been shown to improve asthma symptoms and pulmonary function. New directions in asthma therapy include treatment with monoclonal antibodies directed against IgE and specific cytokines involved in the inflammatory response in asthma.
在过去一年中,哮喘治疗取得了一些重要进展,尤其是在儿童哮喘治疗方面。新指南强调,对于有持续症状的患者,在诊断后应尽早进行抗炎治疗。最近的研究证实,吸入性类固醇是治疗轻度哮喘儿童最有效的疗法,不过这些研究也表明了其存在不良反应的可能性。茶碱或沙美特罗联合治疗可能使临床医生在控制症状的同时,将吸入性类固醇的剂量减至最低。新型高效吸入性类固醇制剂在治疗重度哮喘患者方面显然有效,但高剂量使用时可能会引起显著的副作用。抗白三烯药物可能有助于持续性哮喘的管理,因为已证明它们可改善哮喘症状和肺功能。哮喘治疗的新方向包括使用针对IgE和参与哮喘炎症反应的特定细胞因子的单克隆抗体进行治疗。